-
-
-
-
-
-
-
Syndax presents Revuforj clinical data across acute leukemia subtypes
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) PT Raised to $46 at Stifel on Revuforj Confidence
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) PT Lowered to $40 at Jefferies
-
-
-
-
-
-
-
TD Cowen on Syndax Pharmaceuticals (SNDX): 'We found the updates at ASH generally encouraging'
-
-
-
-
-
-
-
FDA approves Syndax Pharmaceuticals' (SNDX) revumenib for myeloid leukemia
-
-
-
-
-
-
-
B.Riley Assumes Syndax Pharmaceuticals (SNDX) at Buy
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) PT Lowered to $35 at UBS
-
456,518 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

